Genetic aberrations in oligodendroglial tumours: An analysis using comparative genomic hybridization (CGH)

Journal of Pathology

Volumn 188, Issue 3, 1999, Pages 282-288

  Kros, Johan M ^a   Van Run, Peter R W A ^a   Alers, Janneke C ^a   Beverloo, H Berna ^a   Van Den Bent, Martin J ^a   Avezaat, Cees J J ^a   Van Dekken, Herman ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chromosomal aberration; Comparative genomic hybridization; Genetics; Glioma; Mixed oligoastrocytoma; Oligodendroglioma

Indexed keywords

ADULT; ARTICLE; ASTROCYTOMA; AUTOSOME; CHROMOSOME ABERRATION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; MALE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; TUMOR CLASSIFICATION;

ADULT; CHROMOSOME ABERRATIONS; FEMALE; GLIOMA; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PARAFFIN EMBEDDING;

EID: 0033053057     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199907)188:3<282::AID-PATH355>3.0.CO;2-S     Document Type: Article

References (42)

1. Glass J, Hochberg FH, Gruder ML, Louis DN, Smith D, Rattner B. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 1992; 76: 741-745.
2. Kyritsis AP, Yung WK, Bruner J, Gleason MJ, Levin VA. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 1993; 32: 365-370.
3. Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumours of the Central Nervous System. World Health Organization International Histological Classification of Tumours, 2nd edn. Berlin Heidelberg: Springer-Verlag, 1993.
4. Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818-821.
5. Kallioniemi A, Kallioniemi A, Piper J, et al. Optimizing comparative genomic hybridisation for analysis of DNA sequence copy number changes in solid tumours. Genes Chromosomes and Cancer 1994; 10: 231-243.
6. Bentz M, Plesch A, Stilgenbauer S, Döhner H, Lichter P. Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chrom Cancer 1998; 21: 172-175.
7. Alers JC, Krijtenburg PJ, Rosenberg C, et al. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest 1997; 77: 437-448.
8. Kraus JA, Koopmann J, Kaskel P, e alt Shared allelic losses on chromosomes Ip and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Esp Neurol 1995; 54: 91-95.
9. Bello MJ, Leone PE, Vaquero J, et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995; 64: 207-210.
10. Zhu JJ, Santarius T, Wu X, et al. Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas. Genes Chrom Cancer 1998; 21: 207-216.
11. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994; 145: 1175-1190.
12. Von Deimling A, Louis DN, von Ammon K, Peterson I, Wiestler OD, Seizinger BR. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992; 52: 4277-4279.
13. Rosenberg JE, Lisle DK, Burwick JA, et al. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 1996; 13: 2483-2485.
14. Bello MJ, Vaquera J, de Campos JM, et al. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer 1994; 57: 172-175.
15. Rosso SM, van Dekken H, Krishnadath KK, Alers JC, Kros JM. Detection of chromosomal changes by interphase cytogenetics in biopsies of recurrent astrocytomas and oligodendrogliomas. J Neuropathol Exp Neurol 1997; 56: 1125-1131.
16. Weber RG, Sabel M, Reifenberger J, et al. Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene 1996; 13: 983-994.
17. Rey JA, Bello MJ, de Campos JM, Kusak ME, Moreno S. Chromosomal composition of a series of 22 human low-grade gliomas. Cancer Genet Cytogenet 1987; 29: 223-237.
18. Ransom DT, Ritland SR, Kimmel DW, et al. Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosomes Cancer 1992; 5: 348-356.
19. Griffin CA, Long PP, Carson BS, Brem H. Chromosome abnormalities in low-grade central nervous system tumors. Cancer Genet Cytogenet 1992; 60: 67-73.
20. Thiel G, Losanowa T, Kintzel D, et al. Karyotypes in 90 human gliomas. Cancer Genet Cytogenet 1992; 58: 109-120.
21. Magnani I, Guerneri S, Pollo B, et al. Increasing complexity of the karyotype in 50 human gliomas. Progressive evolution and de novo occurrence of cytogenetic alterations. Cancer Genet Cytogenet 1994; 75: 77-89.
22. Pruchon E, Chauveinc L, Sabatier L, et al. A cytogenetic study of 19 recurrent gliomas. Cancer Genet Cytogenet 1994; 76: 85-92.
23. Wu JK, Folkerth RD, Ye Z, Darras BT. Aggressive oligodendroglioma predicted by chromosome 10 restriction fragment length polymorphism analysis. Case study. J Neurooncol 1993; 15: 29-35.
24. Sato K, Schauble B, Kleihues P, Ohgaki H. Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumours. Int J Cancer 1996; 66: 305-308.
25. Li Y-H, Hoang-Xuan K, Delattre J-Y, Poisson M, Thomas G, Hamelin R. Frequent loss of Heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 1995; 11: 597-600.
26. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet 1997; 15: 356-362.
27. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/ MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54: 6321-6324.
28. Jen J, Harper JW, Bigner SH, Bigner DD, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994; 54: 6353-6358.
29. Moulton T, Samara G, Chung W-Y, et al. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 1995; 146: 613-619.
30. Sonoda Y, Yoshimoto T, Sekiya T. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene 1995; 11: 2145-2149.
31. Perry A, Nobori T, Ru N, et al. Detection of p16 gene deletions in gliomas: A comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol 1997; 56: 999-1008.
32. Kim DH, Mohapatra G, Bollen A, Waldman FM, Feuerstein BG. Chromosomal abnormalities in glioblastoma multiforme tumors and glioma cell lines detected by comparative genomic hybridization. Int J Cancer 1995; 60: 812-819.
33. Bardot V, Dutrillaux AM, Luccioni C, et al. Chromosome abnormalities in and adenine metabolism in human glial tumors. Rev Neurol (Paris) 1992; 148:408-416.
34. Schröck E, Thiel G, Lozanova T, et al. Comparative genomic hybridization of human malignant gliomas reveals multiple amplification sites and non-random chromosomal gains and losses. Am J Pathol 1994; 6: 1203-1218.
35. Mohapatra G, Bollen AW, Kim DH, et al. Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade. Genes Chrom Cancer 1998; 21: 195-206.
36. Muleris M, Almeida A, Dutrillaux AM, et al. Oncogene amplification in human gliomas: a molecular cytogenetic analysis. Oncogene 1994; 9: 2717-2722.
37. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997; 10: 1098-1105.
38. Louis DN. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994; 53: 11-21.
39. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P. p53 mutations in non-astrocytic human brain tumors. Cancer Res 1991; 51: 6202-6205.
40. Reifenberger J, Ring GU, Gies U, et al. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 1996; 55: 822-831.
41. Sallinen S-L, Sallinen P, Haapasalo H, et al. Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas. Am J Pathol 1997; 151: 1799-1807.
42. Nishizaki T, Ozaki S, Harada K, et al. Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization. Genes Chrom Cancer 1998; 21: 340-346.